Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for Mereo BioPharma (MREO) over the last 4 years, with Q3 2025 value amounting to $799.9 million.

  • Mereo BioPharma's Shares Outstanding (Weighted Average) rose 386.94% to $799.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $799.9 million, marking a year-over-year increase of 386.94%. This contributed to the annual value of $739.6 million for FY2024, which is 1215.71% up from last year.
  • As of Q3 2025, Mereo BioPharma's Shares Outstanding (Weighted Average) stood at $799.9 million, which was up 386.94% from $799.4 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma's Shares Outstanding (Weighted Average) ranged from a high of $799.9 million in Q3 2025 and a low of $26.96 during Q4 2021
  • For the 4-year period, Mereo BioPharma's Shares Outstanding (Weighted Average) averaged around $666.6 million, with its median value being $739.6 million (2024).
  • Per our database at Business Quant, Mereo BioPharma's Shares Outstanding (Weighted Average) surged by 1243.44% in 2024 and then skyrocketed by 380.3% in 2025.
  • Over the past 4 years, Mereo BioPharma's Shares Outstanding (Weighted Average) (Quarter) stood at $26.96 in 2021, then skyrocketed by 2446026436.82% to $659.5 million in 2023, then grew by 12.16% to $739.6 million in 2024, then rose by 8.16% to $799.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $799.9 million in Q3 2025, compared to $799.4 million in Q2 2025 and $784.3 million in Q1 2025.